Clinical Trials Study
Copyright ©The Author(s) 2021.
World J Gastroenterol. Mar 14, 2021; 27(10): 959-975
Published online Mar 14, 2021. doi: 10.3748/wjg.v27.i10.959
Table 3 Changes in laboratory and imaging variables from baseline during the trial
Parameter
Baseline
6 mo
P value
ТС (total sample), mmol/L6.03 ± 1.365.76 ± 1.21< 0.001
Men5.99 ± 1.395.77 ± 1.240.003
Women6.11 ± 1.325.73 ± 1.160.019
LDL (total sample), mmol/L3.86 ± 1.013.66 ± 0.91< 0.001
Men3.81 ± 1.043.67 ± 0.900.033
Women4.0 ± 0.943.65 ± 0.930.006
HDL (total sample), mmol/L1.24 ± 0.321.24 ± 0.270.910
Men1.24 ± 0.331.21 ± 0.220.160
Women1.23 ± 0.291.31 ± 0.340.036
TG (total sample), mmol/L3.18 (2.00; 4.29)2.04 (1.40; 3.16)< 0.001
Men3.13 (2.10; 4.29)2.04 (1.4; 2.79)< 0.001
Women3.45 (1.80; 4.36)2.26 (1.35; 3.62)< 0.001
FLI (total sample)84.9 ± 10.472.3 ± 17.6< 0.001
Men86.3 ± 9.073.6 ± 17.2< 0.001
Women81.9 ± 12.769.4 ± 18.4< 0.001
FLI (total sample) ≥ 60/30-59/< 30174 (100)/-/- 133 (76.4)/40 (23.0)/1 (0.6)< 0.001
Men121 (100)/-/-96 (79)/24 (20)/1 (1)< 0.001
Women53 (100)/-/-37 (70)/16 (30)/-< 0.001
NFS (total sample) < -1.455 (F0-F2), n (%)141 (81.0)148 (85.0)0.353
Men102 (84.3)112 (92.6)0.071
Women39 (76.6)34 (64.2)0.402
FIB 4 (total sample) < 1.45 (F0-F1), n (%)157 (90.2)163 (93.7)0.256
Men111 (91.7)114 (94.2)0.615
Women46 (86.8)49 (92.5)0.402
CIMT (total sample), mm0.985 ± 0.2430.968 ± 0.2370.013
Men0.993 ± 0.2240.977 ± 0.2170.073
Women0.967 ± 0.2840.947 ± 0.2760.052
CIMT (total sample) exceeding ULN for the corresponding age and sex143 (84)139 (82)0.549
Men103 (85.1)101 (83.5)0.860
Women40 (75.5)38 (72)0.826
ASCVD (total sample, n = 112) 10-year risk5.1 (2.9; 9.1)4.8 (2.6; 8.0)0.053
Men (n = 71)6.0 (3.6; 11.1)5.8 (3.4; 8.8)0.720
Women (n = 41)3.5 (2.3; 7.8)3.2 (2.0; 6.0)0.003
ASCVD (total sample, n = 152) lifetime risk50 (39; 60)50 (39; 64)0.370
Men (n = 112)50 (46; 69)50 (46; 69)0.870
Women (n = 40)39 (39; 50)39 (39; 50)0.160